Head and Neck Cancer Market to Expand at 7.8% CAGR During 2026-2030 as Immuno-Oncology Therapies Offer Promising Advances in HNC Treatments [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Head and Neck Cancer (HNC) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global head and neck cancer (HNC) market is poised for significant growth, with projections indicating an increase from $2.16 billion in 2025 to $2.33 billion in 2026 at a CAGR of 7.8%. By 2030, the market is expected to reach $3.12 billion, fueled by investments in precision oncology, demand for minimally invasive treatments, and advancement in AI-assisted diagnostics. Growth drivers include a rise in tobacco and alcohol consumption, an increase in HPV-related cancer cases, and a boost in oncology treatment infrastructure. Moreover, enhanced diagnostic technologies and heightened awareness of head and neck cancers are pivotal. The forecast period highlights a trend toward targeted treatments, immunotherapies, and advanced imaging techniques, alongside a shift to early cancer detection and multimodal treatment strategies. Elevat
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Ozempic copies for $14 as the generic GLP-1 era starts in India [Los Angeles Times (CA)]Los Angeles Times
- India's Zydus, Lupin sign deal to co-market Semaglutide injections [Yahoo! Finance]Yahoo! Finance
- Strait of Hormuz standoff puts supply of America's generic drug prescriptions at risk [MSNBC.com]MSNBC.com
- India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 1/22/26 - Beat
RDY
Sec Filings
- 4/1/26 - Form 3
- 4/1/26 - Form 3
- 4/1/26 - Form 3
- RDY's page on the SEC website